{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-25-005284","form_type":"8-K","ticker":"CNSP","cik":"0001729427","company_name":"CNS Pharmaceuticals, Inc.","filed_at":"2025-07-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.823055+00:00","generated_at":"2026-05-18T04:24:28.574235+00:00","sec_items":["3.03","5.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CNS Pharmaceuticals announces 1-for-12 reverse stock split effective July 22, 2025","bullets":["Reverse split reduces outstanding shares from ~6.36M pre-split to ~529,829 post-split.","Authorized common shares reduced from 300M to 25M; preferred from 5M to 416,667.","No fractional shares; cash in lieu for odd lots.","CUSIP changes to 18978H508; trading symbol CNSP unchanged.","Historical per-share data recast: FY2024 basic loss per share goes from ($38.87) pre-split to ($466.43) post-split."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-25-005284","json":"https://secwatch.observer/filing/0001683168-25-005284.json","markdown":"https://secwatch.observer/filing/0001683168-25-005284.md","text":"https://secwatch.observer/filing/0001683168-25-005284.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1729427/000168316825005284/0001683168-25-005284-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1729427/000168316825005284/cns_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T04:24:28.574235+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"51a532007ab1d80d84f13163d7452e6c41e8181d","claim":"CNS Pharmaceuticals, Inc.: Certificate of Change filed to effect a 1-for-12 reverse stock split, proportionally reducing authorized common stock from 300,000,000 to 25,000,000 and preferred stock from 5,000,000 to 416,667 (effective 2025-07-22).","evidence_excerpt":"On July 17, 2025, CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), filed with the Secretary of State of the State of Nevada a Certificate of Change (the “Certificate of Change”), pursuant to Nevada Revised Statutes 78.209, to effect a one-for-twelve (1-for-12) reverse stock split (the “Reverse Split”) of the Company’s issued and outstanding common stock, par value $0.001 per share (the “Common Stock”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316825005284/0001683168-25-005284-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2025-07-22"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}